Inflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.
Inflammation and metabolic stress interact in T2DM, and while therapies like liraglutide may improve glycaemic control, their effects on inflammation and long-term disease progression are not yet clear.
Where it sits
this study against the rest of the liraglutide corpusSummary and findings
This narrative review examines the relationship between inflammatory signaling and pancreatic β-cell dysfunction in type 2 diabetes mellitus (T2DM). It evaluates various therapeutic strategies, including liraglutide, aimed at preserving β-cell function. The review highlights the complexity of interactions between metabolic stress and inflammation in T2DM.
Abstract
<h4>Purpose</h4>Inflammatory signalling within and around pancreatic islets is increasingly recognised as an important component of β-cell dysfunction in type 2 diabetes mellitus (T2DM). Current evidence, however, supports a bidirectional relationship in which metabolic stress initiates inflammatory responses and inflammation subsequently amplifies β-cell dysfunction, rather than inflammation acting as a single primary cause of T2DM. This review critically examines the evidence linking metabolic stress to β-cell inflammatory injury and evaluates therapeutic strategies aimed at preserving β-cell function.<h4>Methods</h4>PubMed and Web of Science were searched without a lower publication-date restriction through 1 June 2026, with Google Scholar used as a supplementary source. Search strategies combined terms related to T2DM, pancreatic β-cells/islets, inflammatory and metabolic stress pathways, and therapeutic interventions using the Boolean operators AND and OR. A representative search strategy was: ("type 2 diabetes mellitus" OR T2DM) AND ("pancreatic β-cell" OR "pancreatic islet") AND (inflammation OR glucotoxicity OR lipotoxicity OR "oxidative stress" OR "endoplasmic reticulum stress" OR inflammasome OR cytokine) AND (therapy OR treatment OR protection OR regeneration). Reference lists of relevant reviews and primary studies were also screened to identify additional publications.<h4>Results</h4>Evidence from human and experimental studies supports interactions among glucotoxicity, lipotoxicity, oxidative and endoplasmic reticulum stress, mitochondrial dysfunction, islet macrophage activation, cytokine signalling, and β-cell dysfunction. In contrast, evidence for the causal importance of individual inflammasome, regulated cell-death, extracellular-vesicle, and gene-regulatory pathways remains predominantly preclinical. Randomised trials have reported improvements in glycaemic control or β-cell functional indices with anakinra, salsalate, liraglutide, dapagliflozin, thiazolidinediones, and short-term intensive insulin therapy. However, these trials generally assessed metabolic or β-cell functional outcomes rather than pancreatic islet inflammation directly. Canakinumab did not reduce new-onset diabetes or provide sustained glycaemic improvement, whereas regenerative and gene-editing approaches remain experimental.<h4>Conclusion</h4>Inflammatory signalling and metabolic stress interact bidirectionally and contribute to progressive β-cell dysfunction in T2DM. Selected anti-inflammatory and glucose-lowering interventions improve glycaemic or β-cell functional outcomes, but direct suppression of pancreatic islet inflammation and durable modification of T2DM progression have not been established. IL-1 pathway modulation warrants further investigation, whereas regenerative and gene-based approaches remain experimental. Patient stratification based on β-cell functional status and inflammatory profiles requires prospective validation before clinical implementation.
Background
This paper addresses the role of inflammatory mechanisms in pancreatic β-cell dysfunction related to type 2 diabetes mellitus (T2DM). Prior knowledge indicates that both metabolic stress and inflammation contribute to β-cell injury, but the exact nature of their interaction is complex. This study is significant as it evaluates therapeutic strategies that may mitigate β-cell dysfunction, which is crucial for managing T2DM.
Methods
The authors conducted a narrative review based on literature searches in PubMed and Web of Science, supplemented by Google Scholar. The search included terms related to T2DM, pancreatic β-cells, and various stress pathways. No specific n, dose, or duration were reported as this is a review rather than an original research study.
Results
The review highlights interactions among glucotoxicity, lipotoxicity, and other stress factors affecting β-cell function. It notes that while some interventions like liraglutide show improvements in glycaemic control, the direct impact on islet inflammation was not assessed. Specific numeric findings were not provided.
Interpretation
The findings suggest that while certain therapies may improve glycaemic control, the clinical significance of these improvements in relation to β-cell inflammation is unclear. The review emphasizes the need for further investigation into the IL-1 pathway and the potential of regenerative approaches, which are still experimental. Limitations include reliance on preclinical studies and the absence of direct clinical evidence linking interventions to inflammation reduction.
Key findings
- Randomised trials reported improvements in glycaemic control or β-cell functional indices with liraglutide.
- Canakinumab did not reduce new-onset diabetes or provide sustained glycaemic improvement.
- Evidence for individual inflammasome and gene-regulatory pathways remains predominantly preclinical.
Limitations
- Review does not provide direct evidence for the effects of interventions on pancreatic islet inflammation.
- Evidence for individual pathways remains predominantly preclinical.
- No specific n, dose, or duration reported.